FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Anita Boyapati, PhD, discussed her research on the link between soluble BCMA and both disease burden and response to BCMA-targeted therapies in this patient population.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol in thrombocytopenic myelofibrosis.
ements in recurrence-free survival or overall survival. Advances in the efficacy of systemic therapy options, including the introduction of immune checkpoint inhibitors, have fueled renewed…
A breast cancer breakthroughs fundraising event, where you’ll learn about the progress our dedicated physician-scientists have made for today’s patients and the discoveries they’re pursuing…
Advancements in Genitourinary Cancers: From Guidelines to Patient-Centered Care
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
The sNDA is supported by data from the phase 3 LAURA trial.
ficant results could lead to inappropriate recommendations that increase health care costs and treatment toxicity. Methods: CER studies from 2022 issues of the Annals of…
An abstract is unavailable.